Posted by Michael Wonder on 20 Aug 2024
ReAlta Life Sciences granted FDA orphan drug designation and fast track designation for RLS-0071 for the treatment of steroid-refractory acute graft versus host disease
19 August 2024 - Second clinical indication for RLS-0071 to receive both orphan drug designation and fast track designation, demonstrating the broad potential of ReAlta’s lead dual action complement and innate inflammatory inhibitor.
ReAlta Life Sciences today announced that the US FDA has granted orphan drug designation and fast track designation to RLS-0071, the Company’s lead therapeutic candidate, for the treatment of hospitalised patients with steroid refractory acute graft versus host disease.
